Because Good Medicine Deserves Better Explanations
At first, they were diabetes drugs.
GLP-1 receptor agonists—liraglutide, semaglutide, and later tirzepatide—were developed to help patients with type 2 diabetes regulate blood sugar. They mimicked a gut hormone, GLP-1, that modulates insulin, glucagon, and gastric emptying. They also acted on the brain.
Appetite went down.
Weight came off.
And people noticed.
We’ve become a society defined by distraction, acceleration, and mental erosion. The fog isn’t a glitch. It’s the weather report.
Not long ago, I saw a 58-year-old man who had done “everything right.” His LDL cholesterol (LDL-C) was well controlled on a statin, his blood pressure stable, and he exercised regularly. But he carried extra weight around his waist, his triglycerides were persistently high, and a CT scan revealed clear signs of atherosclerosis in his … Read more
Just days ago, something remarkable happened.
FDA Commissioner Marty Makary stood at a podium and said what would’ve once been unthinkable.
That dogma still lives large,” he declared, referring to America’s decades-long war on saturated fat. “You see remnants of it in the food guidelines that we are now revising.”
It wasn’t just a revision. It was a rebuke.
Makary didn’t mince words. He called the foundational science behind decades of dietary advice—especially…
Sometimes, the most dangerous number isn’t the one your doctor talks about. While LDL-cholesterol (LDL-C) steals the spotlight in most lab reports, it’s not always the best predictor of cardiovascular risk. Hidden in plain sight is a more powerful marker: non-HDL cholesterol (non-HDL-C)—a measure that captures all the cholesterol carried by atherogenic, plaque-building particles, not … Read more